Bing Xiong

Bing Xiong


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SLShuiquan Li
Shuiquan Li
XCXi Chen
Xi Chen
HSHui Shi
Hui Shi
MYMing Yi
Ming Yi
BXBing Xiong
Bing Xiong
TLTianye Li
Tianye Li
Cancer remains a formidable global health challenge, necessitating innovative therapeutic approaches to enhance treatment efficacy and reduce adverse effects. The traditional Chinese medicine (TCM), as an embodiment of ancient wisdom, has been validated to regulate the holistic human capacity against both internal and external “evils” in accordance with TCM principles. Therefore, it stands to reason to integrate TCM into current cancer therapy paradigms, such as chemotherapy, immunotherapy, and targeted therapy. This strategy conceptually intends to circumvent the inevitable side effects derived from present treatment, alleviate the discomfort, mollify the detrimental mood and synergize tumoricidal effects of distinct approaches. However, it is still vague whether TCM exert favorable function in cancer treatment. Therefore, it is imperative to retrieve and compile the existing literature on TCM in the realm of cancer, followed by a comprehensive recapitulation and synthesis of its core findings. Recently, with the advancement of contemporary biologic and medical theory and technology, it has become both feasible and imperative to elucidate the molecular signaling mechanisms and cellular biology underlying TCM. Specifically, leveraging TCM pharmaceutic components can not only directly impact tumor biology at the molecular level, but regulate the tumor immune environment through distinct pathways. Additionally, the administration of external TCM treatments such as acupuncture and moxibustion also demonstrates beneficial effects in cancer patients. Through comprehensive analysis, we demonstrated that TCM not only potentially increases the efficacy of conventional cancer treatments, but also significantly mitigates their toxic side effects, thereby prolonging patients’ prognosis and improving their living quality. Furthermore, we have underscored the challenges and prospects associated with the integration of TCM into contemporary oncological practices, placing particular emphasis on the imperative for rigorous clinical trials and molecular investigations to substantiate the efficacy and safety of these combined therapeutic approaches. This synthesis aims to pave the way for a more integrated approach to cancer treatment rooted in both traditional wisdom and cutting-edge science.

1 December 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Open access
YJYing Jin
Ying Jin
XYXiaoshuai Yu
Xiaoshuai Yu
SHShen Hu
Shen Hu
LLLanying Liu
Lanying Liu
BWBin Wang
Bin Wang
LWLiquan Wang
Liquan Wang
Electroacupuncture is a nonpharmacologic intervention for analgesia that is widely recognized as therapy for pain. However, the clinical efficacy of electroacupuncture combined with patient-controlled intravenous analgesia for postoperative analgesia after cesarean delivery remains unclear. This study aimed to assess the efficacy of electroacupuncture + patient-controlled intravenous analgesia for postoperative analgesia after cesarean delivery, determine the optimal frequency for the best analgesic effect, and explore the underlying mechanism of action. This single-center, randomized, single-blinded, sham acupuncture controlled clinical trial was conducted at a tertiary university hospital in China. Female patients who underwent cesarean delivery and received fentanyl as patient-controlled intravenous analgesia for postoperative analgesia were enrolled. Patients were after surgery randomized to receive 2 Hz electroacupuncture treatment (n=53), 20/100 Hz electroacupuncture treatment (n=53), or sham electroacupuncture treatment (n=52) (controls). The 2 electroacupuncture groups received electroacupuncture treatment at 2 or 20/100 Hz at the ST36 and SP6 points, whereas, in the sham electroacupuncture group, sham electroacupuncture was performed at nonmeridian points with nonenergized electroacupuncture instruments. Of note, 4 electroacupuncture treatments were performed in all groups at 6, 12, 24, and 48 hours after surgery. The primary outcome was the number of analgesic pump compressions at 48 hours after surgery. The secondary outcomes included number of analgesic pump compressions at 6, 12, and 24 hours after surgery; pain scores at 6, 12, 24, and 48 hours after surgery; fentanyl consumption at 48 hours after surgery; interleukin 6 and procalcitonin levels at 12 and 48 hours after surgery; and time to first exhaust. Overall, 174 primigravida women were included in the intention-to-treat analysis. The number of analgesic pump compressions and pain scores at all 4 time points and fentanyl consumption at 48 hours after surgery were significantly lower in the electroacupuncture treatment groups than in the sham electroacupuncture group (P<.001). Electroacupuncture + patient-controlled intravenous analgesia had a significantly better analgesic effect than sham electroacupuncture + patient-controlled intravenous analgesia within 48 hours after surgery. Thus, electroacupuncture can be considered safe and effective and may improve the efficacy of patient-controlled intravenous analgesia for pain management after cesarean delivery. Electroacupuncture can be recommended as a routine complementary therapy for pain control after cesarean delivery.

23 February 2021 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
BXBing Xiong
Bing Xiong
TYTang Yinshan
Tang Yinshan
JYJin Ying
Jin Ying
SYShen Yingchuan
Shen Yingchuan
Objective: To compare the efficacy and safety of a new modified method of bedside post-pyloric feeding tube catheterization with the Corpak protocol versus electromagnetic-guided catheterization. Materials and Methods: We conducted a single-center, single-blinded, prospective clinical trial. Sixty-three patients were treated with a non-gravity type gastrointestinal feeding tube using different procedures: modified bedside post-pyloric feeding tube placement (M group), the conventional Corpak protocol (C group), and standard electromagnetic-guided tube placement (EM group). Results: The success rate in the M group, C group, and EM group was 82.9% (34/41), 70.7% (29/41), and 88.2% (15/17), respectively, with significant differences among the groups. The time required to pass the pylorus was significantly shorter in the M group (26.9 minutes) than in the C group (31.9 minutes) and EM group (42.1 minutes). The proportion of pylorus-passing operations completed within 30 minutes was significantly higher in the M group than in the C group and EM group. No severe complications occurred. Conclusion: This modified method of bedside post-pyloric feeding tube catheterization significantly shortened the time required to pass the pylorus with no severe adverse reactions. This method is effective and safe for enteral nutrition catheterization of patients with dysphagia and a high risk of aspiration pneumonia.

22 December 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
YJYing Jin
Ying Jin
JZJie Zhou
Jie Zhou
YFYinfeng Fang
Yinfeng Fang
HSHongyun Song
Hongyun Song
SLShiming Lin
Shiming Lin
BXBing Xiong
Bing Xiong

1 June 2026 in Stroke
Verified
Journal Article
Closed access
LTLi-Li Tang
Li-Li Tang
YHYu-Hui Huang
Yu-Hui Huang
YJYujia Jin
Yujia Jin
KYKai-Cheng Yang
Kai-Cheng Yang
QLQing Lin
Qing Lin
LTLusha Tong
Lusha Tong
BACKGROUND: Novel stroke risk factors have received widespread attention. This study examined the association between sarcopenia status, grip strength, and walking pace with incident stroke (any stroke, ischemic stroke, and hemorrhagic stroke) and poststroke mortality. METHODS: This prospective study included 482 699 participants from the UK Biobank, a large-scale, population-based cohort. Sarcopenia status was assessed according to the EWGSOP2 criteria (European Working Group on Sarcopenia in Older People 2). Incident strokes were ascertained based on health records. Stroke risk was assessed using multivariable-adjusted Cox proportional hazards models, whereas poststroke mortality was compared using the Kaplan-Meier analysis with log-rank tests. A 2-sample Mendelian randomization analysis, utilizing genetic instruments from public genome-wide association studies, was conducted to infer causal associations. RESULTS: The cohort (mean age±SD: 56.4±8.1 years; 45.37% were men; n=219 015) had a probable sarcopenia prevalence of 4.7% and a confirmed sarcopenia prevalence of 0.4%. Participants with probable sarcopenia had a higher risk of any stroke (adjusted hazard ratio [aHR], 1.30 [95% CI, 1.21−1.39]), ischemic stroke (aHR, 1.31 [95% CI, 1.22−1.42]), and hemorrhagic stroke (aHR, 1.41 [95% CI, 1.20−1.67]) than those without. Among those who had a stroke, probable or confirmed sarcopenia was associated with increased all-cause mortality. Higher risk of any stroke was associated with lower grip strength (absolute: aHR, 1.07 [95% CI, 1.06−1.09] per 5 kg; relative: aHR, 1.36 [95% CI, 1.28−1.44] per 1 kg/[kg/m 2 ]) and a slow walking pace (aHR, 1.64 [95% CI, 1.54−1.75]; compared with brisk pace). Mendelian randomization analysis demonstrated that a faster walking pace was associated with a lower risk of any stroke (odds ratio, 0.94 [95% CI, 0.90−0.97] per-SD increase) and ischemic stroke (odds ratio, 0.95 [95% CI, 0.91−0.98] per-SD increase). CONCLUSIONS: Sarcopenia status, lower grip strength, and slower walking pace were associated with an increased risk of incident stroke and all-cause poststroke mortality.

20 November 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
BXBing Xiong
Bing Xiong
XWXinyuan Wang
Xinyuan Wang
XXXin Xu
Xin Xu
ZLZhilai Lou
Zhilai Lou
TTTing Tong
Ting Tong
HLHuanhuan Liu
Huanhuan Liu
Objective: To evaluate the effectiveness and safety of the MI-R1 lower-limb walking assist device for gait training in subacute stroke patients. Methods: The experimental group received lower-limb function training using the lower-limb training device. In contrast, the control group received lower-limb function training provided by a therapist. After 4 weeks, the patients were evaluated for certain indicators. The primary outcome was the Fugl–Meyer Assessment Lower Extremity score on day 28 (±7 days). The secondary outcomes included the Functional Ambulation Category score, Modified Barthel Index score, safety indicators, and incidence of adverse events. Results: After treatment, the noninferiority statistic between the experimental and control groups was −0.1976 (−1.5051, 1.1099). The lower limit of the 95% confidence interval was greater than the noninferiority margin. There was no significant difference in the Functional Ambulation Category or Modified Barthel Index scores between the experimental and control groups at 0, 14, and 28 days ( p  >   0.05). There was no statistically significant difference in vital signs or adverse event rates between the experimental and control groups ( p  >   0.05). Conclusions: The MI-R1 lower-limb walking assist device is not inferior to traditional rehabilitation in achieving lower-limb function recovery in subacute stroke patients and is associated with good patient safety. Trial registration: ClincialTrials, Unique identifier: NCT06564480 (retrospectively registered)